Aclaris Therapeutics, Inc. 8-K

What Happened

• On January 12, 2026, Aclaris Therapeutics, Inc. filed a Form 8-K (Regulation FD disclosure) to announce an updated corporate overview presentation. The presentation is furnished as Exhibit 99.1 to the filing and is also available on the company’s website. The report was signed by Kevin Balthaser, Chief Financial Officer.

Key Details

• Filing date: January 12, 2026.
• Exhibit furnished: 99.1 — Company Presentation (updated corporate overview).
• Additional exhibit: 104 — cover page formatted in Inline XBRL.
• Report executed by: Kevin Balthaser, Chief Financial Officer.

Why It Matters

• This 8-K is a Regulation FD disclosure providing updated investor materials (corporate overview). It gives stakeholders the company’s latest presentation of strategy, pipeline and corporate information in a single, public document.
• The filing does not report earnings, executive changes, mergers, or financial results — it is supplemental investor information rather than a financial-results filing. Investors should review the furnished presentation on Aclaris’s website for specific updates to strategy, product pipeline, or milestones.